Comparison · NCT02753946-sae
ZTI-01 vs Piperacillin Tazobactam: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ZTI-01 vs Piperacillin Tazobactam: serious adverse events. Trial comparisons, record NCT02753946-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02753946-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0215 | 0.0092 | 0.0492 | wilson | |
| Risk in group 2 | 0.026 | 0.012 | 0.0555 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00451 | -0.0365 | 0.0266 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.826 | 0.256 | 2.67 | log | |
| Odds ratio, group 1 over group 2 | 0.822 | 0.247 | 2.73 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on ZTI-01 than on Piperacillin Tazobactam | 221 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ZTI-01 | 6 g ZTI-01 (IV fosfomycin) intravenously administered every 8 hours (18g total daily dose for 7-14 calendar days)~ZTI-01: 6g ZTI-01 intravenous infusion TID q8 hours | 5 | 233 | EG000 |
| Group 2 | Piperacillin Tazobactam | 4.5 g piperacillin/tazobactam (4 g piperacillin/0.5 g tazobactam) intravenously administered every 8 hours (13.5g total daily dose for 7-14 calendar days)~Piperacillin-tazobactam: 4.5g piperacillin-tazobactam intravenous infusion TID q8 hours | 6 | 231 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections
- NCT number
- NCT02753946
- Phases
- PHASE2, PHASE3
- Conditions
- Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
- Interventions
- ZTI-01, Piperacillin-tazobactam
- Lead sponsor
- Nabriva Therapeutics AG
- Results first posted
- 2018-12-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02753946?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02753946-sae